S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.

Research Base: Southwest Oncology Group
NCT ID: NCT03418961
NCI Protocol Number: SWOG-S1501
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Carvedilol; Laboratory Biomarker Analysis; Patient Observation

Condition

Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP